利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.018 秒)

    Process for producing tetrakis(faryl)borate-salts
    1.
    发明申请
    Process for producing tetrakis(faryl)borate-salts 审中-公开
    生产四（faryl）硼酸盐的方法

    公开(公告)号：US20070197831A1

    公开(公告)日：2007-08-23

    申请号：US10589413

    申请日：2004-04-01

    申请人： John Lee ,  Rajeev Mathur

    发明人： John Lee ,  Rajeev Mathur

    IPC分类号： C07F5/02

    CPC分类号： C07F5/027

    摘要： This invention provides a process for producing a protic ammonium tetrakis(Faryl)borate. The process comprises mixing together (a) at least one alkali metal tetrakis(Faryl)borate, at least one magnesium tetrakis(Faryl)borate, at least one halo-magnesium tetrakis(Faryl)borate, or a mixture of two or more of the foregoing, (b) at least one amine, and (c) one or more liquid dihydrocarbyl ethers, one or more liquid hydrocarbons, one or more liquid halogenated hydrocarbons, or a mixture of two or more of the foregoing, to form a solution or slurry in a liquid organic medium. At least one protic acid is mixed together with at least a portion of the solution or slurry formed in i), such that a protic ammonium tetrakis(Faryl)borate is formed. The amine has the formula R3N, in which each R is independently a hydrocarbyl group containing up to about thirty carbon atoms. Each of the Faryl groups is a fluorine-containing aryl group that has bonded directly to an aromatic ring at least two fluorine atoms, or at least two perfluorohydrocarbyl groups, or at least one fluorine atom and at least one perfluorohydrocarbyl group.

    摘要翻译： 本发明提供了一种生产四氨基四氢（P）芳基）质子铵的方法。 所述方法包括将（a）至少一种碱金属四（非 - 氟）芳基）硼酸盐，至少一种四（四丁基）芳基硼酸镁，至少一种卤代 - 或四种（F）芳基）硼酸镁，或上述两种或多种的混合物，（b）至少一种胺，和（c）一种或多种液体二烃基醚，一种或多种液体烃 ，一种或多种液体卤代烃，或两种或更多种前述物质的混合物，以在液体有机介质中形成溶液或浆液。 将至少一种质子酸与i）中形成的溶液或浆料的至少一部分混合在一起，从而形成四氨基四（四氢呋喃）四磷酸铵。 胺具有式R 3 N，其中每个R独立地是含有至多约30个碳原子的烃基。 每一个芳基都是含氟芳基直接与芳环键合至少两个氟原子，或至少两个全氟烃基，或至少一个氟原子，至少有一个氟原子 一个全氟烃基。

    Halide Reduction in Dihydrocarbylmagnesium Mixtures
    2.
    发明申请
    Halide Reduction in Dihydrocarbylmagnesium Mixtures 有权
    二烃基镁混合物中的卤化物还原

    公开(公告)号：US20080023856A1

    公开(公告)日：2008-01-31

    申请号：US11718380

    申请日：2004-11-12

    申请人： Milind Pradhan ,  Chi Cheng ,  Rajeev Mathur ,  Richard Holub ,  Donald Imhoff

    发明人： Milind Pradhan ,  Chi Cheng ,  Rajeev Mathur ,  Richard Holub ,  Donald Imhoff

    IPC分类号： C07F3/02

    CPC分类号： C07F3/02

    摘要： This invention provides a process for reducing the amount of soluble halide in a solution comprising a liquid organic medium, at least one viscosity reducing agent, at least one dihydrocarbylmagnesium compound, and an initial amount of soluble halide. The process comprises mixing at least one alkali metal with the solution at a mole ratio of alkali metal to magnesium of less than about 1:2.5, thereby forming precipitated soluble halides. Also provided by this invention is a process for reducing the amount of soluble halide in a slurry comprising a liquid organic medium, at least one viscosity reducing agent, at least one dihydrocarbylmagnesium compound, solids from the formation of said dihydrocarbylmagnesium compound, and an initial amount of soluble halide. This process comprises mixing at least one alkali metal with the slurry at a mole ratio of alkali metal to magnesium of less than about 1:1.25, thereby forming precipitated soluble halides.

    摘要翻译： 本发明提供一种减少包含液体有机介质，至少一种降粘剂，至少一种二烃基镁化合物和初始量的可溶性卤化物的溶液中的可溶性卤化物的量的方法。 该方法包括将碱金属与镁的摩尔比以小于约1:2.5的比例混合至少一种碱金属与溶液，由此形成沉淀的可溶性卤化物。 本发明还提供一种减少包含液体有机介质，至少一种粘度降低剂，至少一种二烃基镁化合物，形成所述二烃基镁化合物的固体和初始量的浆料中的可溶性卤化物的量的方法 的可溶性卤化物。 该方法包括将碱金属与镁的摩尔比以小于约1：1.25的比例混合至少一种碱金属，从而形成沉淀的可溶性卤化物。

    Stable oral compositions of azithromycin monohydrate
    3.
    发明申请
    Stable oral compositions of azithromycin monohydrate 审中-公开
    稳定的阿奇霉素一水合物的口服组合物

    公开(公告)号：US20070185194A1

    公开(公告)日：2007-08-09

    申请号：US10561827

    申请日：2004-07-01

    申请人： Kamal Mehta ,  Rajeev Mathur ,  Sujata Paul ,  Sanjeev Sethi ,  Rajiv Malik

    发明人： Kamal Mehta ,  Rajeev Mathur ,  Sujata Paul ,  Sanjeev Sethi ,  Rajiv Malik

    IPC分类号： A61K31/35

    CPC分类号： A61K9/0095 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2077 ,  A61K31/70

    摘要： The present invention relates to stable oral compositions of azithromycin monohydrate with reduced bitterness, processes for making these compositions, and methods of using these compositions for the treatment of microbial infections. The stable oral compositions of azithromycin include an azithromycin premix, at least one pharmaceutically accepted excipient, and, optionally, at least one taste-masking agent. The azithromycin premix includes azithromycin monohydrate and at least one additive.

    摘要翻译： 本发明涉及具有降低的苦味的阿奇霉素一水合物的稳定口服组合物，以及制备这些组合物的方法，以及使用这些组合物治疗微生物感染的方法。 阿奇霉素的稳定的口服组合物包括阿奇霉素预混物，至少一种药学上可接受的赋形剂和任选的至少一种掩味剂。 阿奇霉素预混物包括阿奇霉素一水合物和至少一种添加剂。

    Pharmaceutical compositions of ganciclovir
    8.
    发明申请
    Pharmaceutical compositions of ganciclovir 审中-公开
    更昔洛韦的药物组合物

    公开(公告)号：US20060189565A1

    公开(公告)日：2006-08-24

    申请号：US10532024

    申请日：2003-10-22

    申请人： Rajeev Mathur ,  Pananchukunnath Kumar ,  Sunilendu Roy ,  Rajiv Malik

    发明人： Rajeev Mathur ,  Pananchukunnath Kumar ,  Sunilendu Roy ,  Rajiv Malik

    IPC分类号： A61K31/7072

    CPC分类号： A61K9/2077 ,  A61K31/522

    摘要： The technical field of the invention relates to pharmaceutical compositions of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir) that are stable and contain more than 1% water content. One pharmaceutical composition includes ganciclovir having more than about 1% water content, and one or more pharmaceutically acceptable excipients. The ganciclovir retains at least about 97% of its initial purity after one month, at least about 96% of its initial purity after two months, and at least about 95% of its initial purity after three months when stored at 40° C. and 75% RH. In particular, the water content may be between about 2% and about 6%.

    摘要翻译： 本发明的技术领域涉及稳定且含有1％以上含水量的9-（1,3-二羟基-2-丙氧基甲基）鸟嘌呤（更昔洛韦）的药物组合物。 一种药物组合物包括具有超过约1％水含量的更昔洛韦和一种或多种药学上可接受的赋形剂。 更昔洛韦保存至少约97％的初始纯度一个月后，至少约96％的初始纯度两个月后，至少约95％的初始纯度三个月后储存在40°C和 75％RH。 特别地，水含量可以在约2％至约6％之间。